Uptake of gamma-aminobutyric acid by human blood platelets: comparison with CNS uptake

Platelet uptake of GABA and glutamate in patients with bipolar disorder

OBJECTIVES

Gamma aminobutyric acid (GABA) and glutamate (Glu) are the major neurotransmitters of the human central nervous system, and their actions are determined by specific transporters. Several studies suggest that GABA- and Glu-uptake mechanisms are modified in patients with bipolar disorder (BD). We explored the functionality of the GABA and Glu transporters in three groups of patients with BD, each with a different polarity of index episode (manic, depressive, or euthymic) at the time of blood draw.

METHODS

Forty patients with a diagnosis of BD, according to DSM-IV-TR criteria, and 15 healthy subjects were enrolled in the study. GABA and Glu uptake were evaluated in freshly prepared platelets using [(3) H]GABA or [(3) H]glutamate.

RESULTS

Compared to controls, GABA uptake was significantly increased in patients with depressive episodes and significantly decreased in subjects with manic episodes. Glu uptake was significantly increased in patients with index manic episodes and in euthymic patients compared to healthy controls. Moreover, a positive correlation was found between GABA platelet uptake and Hamilton Depression Rating Scale scores and between Glu platelet uptake and Young Mania Rating Scale scores in patients with manic episodes.

CONCLUSIONS

We found a relationship between GABA- and Glu-uptake levels and the polarity of episodes in patients with BD. Our data suggest that the functionality of both GABA and Glu transporters could represent a useful neurobiological marker to characterize the real polarity of an index episode of illness in patients with BD.

Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology

The main component of Alzheimer's disease (AD) senile plaques in the brain is amyloid-beta peptide (Abeta), a proteolytic fragment of the amyloid precursor protein (APP). Platelets contain both APP and Abeta and much evidence suggests that these cells may represent a useful tool to study both amyloidogenic and nonamyloidogenic pathways of APP processing. It has been demonstrated that platelets activated by physiological agonists, such as thrombin and collagen, specifically secrete Abeta ending at residue 40. To verify whether APP beta-processing could be observed also in an in vitro system of highly concentrated platelets, we measured the Abeta released in the incubation media of 5 x 10(9) platelets/mL by enzyme-linked immunosorbent assay (ELISA). The activation status of platelets was investigated by ultrastructural analysis. We found that Abeta(40) levels were significantly higher in incubation media of 5 x 10(9)/mL platelets in comparison with 10(8)/mL platelets (normalized values), while Abeta(42) levels were not affected by cell density. The ultrastructural analysis showed platelets at different phases of activation: some platelets were at earlier stage, characterized by granule swelling and dilution, others had granules concentrated in a compact mass in the cell centers within constricted rings of circumferential microtubules (later stage). Normally concentrated cells had the characteristic morphology of resting platelets. Our data suggest that high-density platelets undergo activation likely by increased frequency of platelet-platelet collisions. This, in turn, determines the activation of APP beta-processing with consequent release of Abeta(40). Investigating the biochemical pathways triggering Abeta secretion in platelets might provide important information for developing tools to modulate this phenomenon in AD brains.

GABA and glutamate transporters are expressed in human platelets

GABA and glutamate are the major neurotransmitters in the human central nervous system. Disturbances in these transmitter systems have been suggested to influence a variety of neurological and psychiatric diseases. Human platelets have been used as a model for neural amino acid transport, although it has not been known exactly which transporters participate in the transport process. In this study, we identify with reverse transcription-polymerase chain reaction (RT-PCR) BGT-1 and EAAT3 as transporters for GABA and glutamate, respectively. We also show that platelets contain transporters for dopamine, taurine and creatine. The cloning of these transporters confirms that blood platelets can be used as a model for neurotransmitter transport in the CNS.

Glutamate uptake in blood platelets from epileptic patients

Glutamate, the major excitatory amino acid neurotransmitter, is involved in epileptogenesis and initiation and spread of seizures. We studied glutamate uptake into blood platelets from patients with distinct epileptic syndromes: included were 20 patients with temporal lobe epilepsy and hippocampal sclerosis (TLE+HS), 20 with juvenile myoclonus epilepsy (JME) and 20 healthy volunteers matched for age and sex. The affinity of glutamate for the transporters was highest in patients with TLE+HS, but the maximal velocity of transport was highest in controls. There were no differences in the plasma levels of glutamate. Carbamazepine (CBZ), valproate (VPA) and lamotrigine (LTG) did not affect the uptake in vitro. The alterations observed in the uptake of glutamate in TLE+HS patients may reflect an up-regulated uptake of glutamate in the brain.

Uptake of GABA and activity of GABA-transaminase in platelets from epileptic patients

The aim of the present study was to assess the activity of GABA-transaminase (GABA-T) and the kinetic parameters of GABA uptake in platelets from patients with distinct epileptic syndromes. We studied 14 patients with juvenile myoclonic epilepsy (JME), 19 patients with refractory localization-related epilepsy (RLE) and 20 healthy volunteers who were matched for age and sex. Acute effects of valproate (VPA) and lamotrigine (LTG) on the uptake of GABA and the activity of GABA-T in platelets in vitro were also analyzed. The mean activity of GABA-T in JME patients was significantly higher than in control subjects, whereas RLE patients did not significantly differ from controls. The capacity of GABA uptake was least in JME patients, intermediate in RLE patients and highest in controls. In vitro VPA (concentrations 150-1200 microM) or LTG (concentrations 1-100 microM) had no significant effects on GABA uptake. Our results indicate marked differences in the platelet uptake of GABA and the activity of catabolic enzyme GABA-T between patients with generalized and localization-related epileptic syndromes. The observed peripheral alterations may indicate an impairment in the function of brain GABAergic systems.

Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients

Blood platelet phenolsulphotransferase and monoamine oxidase activities, as well as platelet peripheral-type benzodiazepine binding have been studied in several neuropsychiatric disorders, in order to identify biochemical markers for altered brain functioning. In the present work, we determined platelet phenolsulphotransferase and monoamine oxidase activities in demented patients: they showed significantly higher phenolsulphotransferase and monoamine oxidase activities than controls. A significant positive correlation was found between enzyme activities and severity of illness. In the same subjects, we evaluated platelet peripheral-type benzodiazepine binding: a significant reduction of Bmax values was observed in demented patients, whereas Kd values did not substantially differ between the two subject groups. These findings are discussed with reference to central nervous system biochemical abnormalities of demented subjects: it may be that in Dementia of Alzheimer type either some central biochemical changes are reflected in certain peripheral tissues (such as platelets), or a systemic derangement occurs together with a cerebral involvement.

Platelet and lymphocyte benzodiazepine binding in patients with Alzheimer's disease

Peripheral blood cells, such as platelets or lymphocytes, have been studied in the investigation of systemic derangements and central nervous system biochemical changes occurring in several neuropsychiatric disorders. In the present work, assaying platelet and lymphocyte peripheral-type benzodiazepine binding in patients with Alzheimer's disease (AD) and healthy controls, we found a significantly reduced number of cell receptors in patients' platelets and lymphocytes. These results are discussed with reference to central nervous system biochemical abnormalities in AD. Moreover, the lymphocyte binding data may represent an impairment of the immune response in AD, since lymphocyte surface peripheral-type benzodiazepine receptors seem to be related to immune function.

Platelet monoamine oxidase molecular activity in demented patients

Blood platelet monoamine oxidase activity, as well as other platelet enzyme activities, have been studied in several neuropsychiatric disorders in an attempt to identify biochemical markers of altered brain function. In this study, we determined both total and molecular monoamine oxidase activity in platelets derived from demented patients, which showed significantly greater enzyme activity than those of the controls. It therefore seems that the high degree of monoamine oxidase activity depends on the increased intrinsic activity of individual enzyme molecules. A significant positive correlation was found between monoamine oxidase activity and the severity of illness, which suggests that monoamine oxidase activity may be a state-dependent marker of neurodegeneration. These findings are discussed with reference to the central nervous system biochemical abnormalities of demented subjects: it may be that Alzheimer-type dementia involves some central biochemical changes that are reflected in certain peripheral tissues (e.g. platelets), or a systemic derangement that also affects the brain.

Huntington's disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma

The neural degeneration observed in the striata of patients with Huntington's disease (HD) can be reproduced by excitatory NMDA receptor agonists such as aspartate and glutamate in striatal cell cultures and in striata of vertebrates injected with these substances. Therefore, we decided to investigate the role of aspartate and glutamate in HD. Aspartate, glutamate, glutamine, and phenylalanine were measured in platelets and plasma of HD patients and age- and sex-matched healthy controls (C), using HPLC methods. In HD platelets the mean aspartate concentration was significantly (p < 0.01) increased (8.9 +/- 3.8 (SD) nmol/mg protein, n = 28) compared to C (4.6 +/- 1.4 (SD) nmol/mg protein, n = 24), whereas plasma aspartate was significantly (p < 0.01) decreased in HD (0.092 +/- 0.023 (SD) mg/dl, n = 16) versus C (0.179 +/- 0.109 (SD) mg/dl, n = 21). The increase in platelet aspartate should be a direct or indirect consequence of the dominant gene defect in HD. It might therefore be present in neurons as well, especially since platelets share many characteristics with neurons. Hence, chronically increased release of aspartate with consecutive overstimulation of postsynaptic neurons via NMDA receptors might be responsible for the damage observed in striatal target cells of corticostriatal glutamatergic and aspartatergic projection fibers in HD.

Effect of vigabatrin (GVG) on serotonin (5-HT) uptake and release of human platelets in vitro

In platelets from healthy persons the effect of gamma-vinyl-GABA (GVG) on 5-HT uptake, storage, release and the kinetic parameters Km and Vmax of platelet 5-HT high affinity uptake was investigated in vitro. 5-HT uptake, storage and release in response to increasing GVG concentrations (0-7.74 mM) at a constant incubation time (60 min) and in dependence on time (0-90 min) at a constant GVG concentration (7.74 mM) remained unchanged. Concerning the high affinity 5-HT uptake, GVG (7.74 mM) caused a slight decrease of Vmax from 83.3 +/- 35.0 (SD) pmol 5-HT/10(8) pl./min to 77.0 +/- 33.4 (SD) pmol 5-HT/10(8) pl./min and a significant elevation of Km from 4.2 +/- 1.1 (SD) x 10(-7) M to 6.7 +/- 1.8 (SD) x 10(-7) M (P < 0.002) to about 160% of the control. This means a competitive inhibition of 5-HT uptake induced by GVG. Altogether, the effects of GVG on platelet 5-HT transport appear to be weak. An alteration of the platelet 5-HT system was demonstrated only at therapeutically nonrelevant high GVG concentrations. If platelets represent a model for 5-HT transport processes in presynaptic serotonergic neurons it is concluded that GVG has no effect on serotonergic activity.

Human blood platelet as research tool in neuropsychopharmacology

The use of blood platelets as a nerve terminal model for serotonin is well documented. However, it is clear that the use of platelets as a model can be justified only for those parameters where it may be shown that blood platelets and neural cells share almost identical features. The excellent similarity between the serotonin transport mechanisms in platelets and in nerve terminals, and the existence of various receptors for biogenic amines, peptides and substances with neuronal activity on platelet membrane offer a really unique opportunity to utilize blood platelets as a system for drug evaluation. In our work platelet benzodiazepine binding sites and their modulation by different benzodiazepines in normals and in demented patients are examined.

Uptake of peptides containing Tyr-Pro by human and mouse erythrocytes

Red blood cells (RBCs) harvested from mice were used to investigate the possible existence of an uptake system for peptides in these cells. The radioactively iodinated tetrapeptide Tyr-MIF-1 (Tyr-Pro-Leu-Gly-amide) was incubated with RBCs for varying lengths of time with or without inhibitors. The RBCs showed saturable uptake that could be inhibited by Tyr-Pro containing peptides. Uptake was also found in human RBCs, but was more robust in the mouse. Uptake by mouse RBCs was temperature dependent and magnesium sensitive but did not require sodium, potassium, or glucose. With the exception of some enkephalin- and dynorphin-related peptides that partially inhibited uptake, most substances tested were without effect. The results of HPLC showed internalization of the N-Tyr-Pro containing peptides, with accumulation of degradation products over time. The degradation products, however, did not inhibit transport, suggesting that peptides were transported intact into the RBCs with degradation occurring after internalization. This suggestion was strengthened by the finding that only the cytosol of the RBC, not its membranes, rapidly degraded Tyr-MIF-1 to free iodine and iodotyrosine. Nevertheless, the cytosol contained a large amount of immunoreactive material that eluted at the position of intact Tyr-MIF-1 on HPLC. These findings show that RBCs can take up, store, and degrade Tyr-Pro containing peptides.

gamma-Aminobutyric acid uptake and localization in bovine chromaffin cells in primary culture

gamma-Aminobutyric acid (GABA) uptake was studied in bovine chromaffin cells maintained in primary culture. Uptake was found to be dependent on Na+, but not on K+ and Ca2+ ions; it was found that 2 Na+ ions were necessary for each molecule of GABA transported. 2,4-Dinitrophenol, ouabain and vanadate inhibited GABA uptake showing the energy dependency of the system. Two affinity sites were demonstrated, a high affinity site and a low affinity site with Km values of 10 microM and 170 microM, respectively. While the low affinity site did not show large variations with culture age, the Km of the high affinity site increased from 1 microM in freshly isolated cells to 10 microM in 3-9 day-old cells. GABA uptake was unaffected by glutamic acid, aspartic acid, glycine and catecholamines, while taurine, beta-alanine, nipecotic acid and L-2,4 diaminobutyric acid inhibited GABA uptake. Nipecotic acid and L-2,4 diaminobutyric acid acted as competitive inhibitors modifying Km values of the high affinity site. Subcellular studies performed on [3H]GABA-loaded chromaffin cells showed that GABA was not in secretory granules but was recovered in the 100,000 g soluble fraction. The GABA uptake process associated with chromaffin cells may be an important mechanism for regulating the modulation of catecholamine secretion. In addition, the presence of GABA in the cytosol indicates that this molecule may be an effector of chromaffin cell activity in addition to modulating catecholamine secretion.

Taurine: an overview of its role in preventive medicine

Taurine (2-aminoethanesulfonic acid), well known for its role in bile salt synthesis, is also involved in a number of crucial physiological processes including modulation of calcium flux and neuronal excitability, osmoregulation, detoxification, and membrane stabilization. With the exception of cow's milk, taurine is widely distributed in foods from many animal, but not plant, sources. Although taurine is synthesized from sulfur-containing amino acids, concern has been expressed about the adequacy of endogenous sources, especially in neonates. Accordingly, proprietary milk formulas are now supplemented with taurine. Retinal dysfunction occurs in taurine-deficient animals. A milder form of this condition has been observed in children on long-term total parenteral nutrition. Preliminary evidence suggests a possible role for taurine administration in congestive heart disease, acute hepatitis, cystic fibrosis, and myotonia. Further studies are required before taurine can be routinely advocated for use in these and other disorders. Recent discoveries concerning taurine's role in cellular proliferation and membrane protection underscore its physiological significance. In this context, taurine's interaction with other nutrients, biochemicals, and xenobiotics warrants extensive exploration. As a conditionally essential nutrient, taurine has several important preventive medical applications.

Uptake and catabolism of gamma-aminobutyric acid by the isolated perfused rat liver

Serum concentrations of gamma-aminobutyric acid (GABA) are increased in liver failure, possibly because of decreased hepatic GABA catabolism. To study in detail the role of the liver in GABA metabolism, uptake and catabolism of GABA by isolated perfused liver from normal rats and rats with galactosamine- or carbon tetrachloride-induced liver failure were measured. Hepatic GABA uptake was almost complete at GABA concentrations of up to 10 microM and approached saturation at a concentration of 50 microM. The apparent affinity of hepatic GABA uptake was 38 microM and the apparent maximal velocity was 158 nmol/g.min. Hepatic GABA uptake was sodium-dependent. gamma-Aminobutyric acid taken up by the liver was rapidly catabolized as measured by 14CO2 formation from [U-14C]GABA. Aminooxyacetic acid, a GABA transaminase inhibitor, completely and irreversibly inhibited hepatic GABA catabolism and thereby also inhibited hepatic GABA uptake. Although uptake of GABA by livers of carbon tetrachloride- or galactosamine-treated rats was decreased (apparent maximal velocity, 103 and 98 nmol/g.min, respectively), at physiologic GABA concentrations in the perfusate GABA uptake and catabolism was not different from that of untreated controls. The observed impairment of hepatic GABA uptake or catabolism by the diseased liver would be expected to contribute to increased GABA levels in peripheral blood plasma in liver failure. However, the magnitude of the observed impairment would be insufficient to account for a 10-fold increase in such levels.

A comparison of methodologies for the study of functional transmitter neurochemistry in human brain

A number of different approaches to the study of functional neurochemistry in human brain are discussed. The advantages and disadvantages of three main techniques are contrasted: (i) using animal tissue preparations as models of the human brain; (ii) using human peripheral tissue preparations as models of dynamic CNS processes; and (iii) studying human tissue, obtained postmortem, directly. Animal models are often readily obtained and reliable, and the high degree of inbreeding of common laboratory animals ensures that they usually yield consistent results. However, there are a number of human disorders for which animal models are either poor or unavailable, and species differences make extrapolation from the animal to the human case difficult. Human peripheral tissue models rely on a degree of homology between peripheral and CNS processes; in most cases, the evidence for such homologies derives from animal, rather than human, studies. Moreover, several examples are known where a peripheral process mimics the equivalent glial cell activity more closely than the neuronal, which can be a serious drawback for studies of neurotransmission. The use of postmortem human brain tissue presents a number of obvious difficulties, resulting from variations in the patient's age, agonal state, sex, preterminal medication, postmortem delay, etc. Human beings are genetically and nutritionally heterogeneous, so that data variability is usually greater here than when using tissue from laboratory animals. However, it is possible to control for a number of these factors, for example, by matching samples for basal metabolic rate and tissue integrity, and recently developed tissue freezing and storage techniques permit the use of within-subject experimental designs to help reduce experimental variation. A range of neurotransmitter functions are well retained in such tissue samples, so that regional variations, differential transmitter activities, drug effects, etc., can be studied in normal tissue samples, as well as in samples taken from cases of neurological and psychiatric disease. This allows, for example, changes in neuroanatomical indices to be correlated with localised alterations in a specific neurotransmitter function. A systematic approach to the analysis and matching of tissue samples is advocated. The three approaches should be considered to be complementary, especially for the study of human brain diseases.

Characterization and localization of high-affinity GABA uptake in slices of the rabbit oviduct

The characteristics of [3H]gamma-aminobutyric acid (GABA) uptake by slices of the rabbit oviduct were studied, and the GABA-accumulating structures were identified by histoautoradiography. A high-affinity (Km = 5 microM), sodium-dependent GABA uptake system was demonstrated which showed significant segmental variation along the oviduct with a maximal capacity (21 nmol/g tissue per h) at the fimbriated ampullary end of the organ. The uptake showed optimum values at pH 7.4 and 37 degrees C and could be influenced by changes of K+ and Ca2+ concentrations in the medium. Unlabelled GABA, ouabain and beta-alanine completely inhibited the uptake process, whereas known inhibitors of neuronal GABA uptake (L-diaminobutyric acid, nipecotic acid) produced only partial inhibition even at high doses. In autoradiographic experiments, epithelial secretory cells were predominantly labelled by [3H]GABA. These findings indicate the presence of a non-neuronal GABA uptake system in the oviductal epithelium and do not support the earlier hypothesis of GABAergic innervation in the oviduct.